JAZZ241220P175000
- 0.00
- 0.000.00%
Jazz Pharmaceuticals Newsroom
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest
Jazz Pharmaceuticals Insider Sold Shares Worth $456,617, According to a Recent SEC Filing
Baupost's Top Q3 Trades Include Jazz Exit, New Dollar General Stake
Jazz (JAZZ) Upgraded to Buy: Here's Why
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Jazz Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
J.P. Morgan Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Radnet (RDNT) and Eli Lilly & Co (LLY)
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $130 to $230
Express News | Jazz Pharmaceuticals PLC : Wells Fargo Raises Target Price to $130 From $120
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Needham Reiterated a Buy Rating on the Stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target
Jazz Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $140 to $207
Jazz Pharmaceuticals | 10-Q: Q3 2024 Earnings Report